Morgan Stanley analyst Michael Ulz raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $81 and keeps an Overweight rating on the shares. The acquisition of Bluejay adds brelovitug, which has demonstrated “promising activity and tolerability” in hepatitis delta virus and expands rare liver disease pipeline while providing synergies, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $88 from $80 at Baird
- Strategic Acquisition Positions Mirum Pharmaceuticals for Leadership in Rare Liver Disease Market
- Strategic Acquisition and Market Potential Drive Buy Rating for Mirum Pharmaceuticals
- Mirum Pharmaceuticals price target raised to $94 from $89 at Evercore ISI
- Mirum’s deal for Bluejay a positive readthrough to Vir, says Needham